Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Anticancer Res. 2012 Mar;32(3):1103-6.
Docetaxel is a well tolerated chemotherapy for non-small cell lung cancer (NSCLC). However, few studies have investigated interstitial lung disease (ILD) associated with docetaxel. The purpose is to describe the incidence of this complication by using NSCLC patients.
Between September 2002 and March 2008, 392 patients with advanced NSCLC were treated with docetaxel and we retrospectively reviewed the radiography. In total, 18 patients subsequently developed ILD associated with docetaxel.
The incidence of ILD associated with docetaxel was 4.6%. In treated patients who showed an interstitial change on chest computed tomography (CT), the incidence was very high (25.9%). Chest radiograph showed diffuse and bilateral ground-glass appearance patterns.
Pre-existing interstitial change on CT was associated with a higher incidence of ILD (25.9%) among NSCLC patients treated with docetaxel. We don't recommend administering docetaxel for the patients with pre-existing interstitial change.
多西他赛是一种耐受性良好的非小细胞肺癌（NSCLC）化疗药物。然而，很少有研究调查与多西他赛相关的间质性肺病（ILD）。本研究旨在通过 NSCLC 患者描述该并发症的发生率。
2002 年 9 月至 2008 年 3 月，392 例晚期 NSCLC 患者接受多西他赛治疗，我们对其影像学进行了回顾性分析。共有 18 例患者随后发生了与多西他赛相关的 ILD。
与多西他赛相关的 ILD 的发生率为 4.6%。在胸部 CT 显示间质性改变的治疗患者中，ILD 的发生率非常高（25.9%）。胸部 X 线表现为弥漫性双侧磨玻璃样外观。
在接受多西他赛治疗的 NSCLC 患者中，CT 上预先存在的间质改变与ILD 发生率较高（25.9%）相关。我们不建议对预先存在间质改变的患者使用多西他赛。
